E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Seasonal Allergic Rhinitis |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this trial is to compare the PK of: • Mometasone + Azelastine, 50 μg/140 μg (per actuation) liquid, nasal spray from Lek Pharmaceuticals d.d., Slovenia; • Mometasone Furoate 50 μg nasal spray (per actuation) from Lek Pharmaceuticals d.d., Slovenia; and • Azelastine Hydrochloride 140 μg (per actuation) nasal spray from Lek Pharmaceuticals d.d., Slovenia; after a single dose which includes 4 actuations (2 actuations in each nostril) in Cohort 1 (12 to 17 years of age) and Cohort 2 (18 to 24 years of age) with Seasonal Allergic Rhinitis.
|
|
E.2.2 | Secondary objectives of the trial |
The secondary objective of this study is to evaluate the safety and tolerability of the study treatments. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Non-smoking, adolescent or young adult male and female subjects with seasonal allergic rhinitis. Willing to use acceptable, effective methods of contraception. Be informed of the nature of the study and give written consent (adults) / assent and consent by legal guardian(s)/parent(s) (adolescents) prior to any study procedure. |
|
E.4 | Principal exclusion criteria |
Known history or presence of clinically significant disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results. Known history or presence of hypersensitivity or idiosyncratic reaction to mometasone, azelastine, or any other drug substances with similar activity. Unable to tolerate direct venipuncture. Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C antibody. Positive test result for urine drugs of abuse or urine cotinine. Presence of nostril or septum piercing. Use of tobacco or nicotine-containing products within 6 months prior to drug administration. Females who are pregnant, breast-feeding, or have used hormonal contraceptives within 21 days (oral and transdermal) or 6 months (implanted, injected, intravaginal, or intrauterine) prior to drug administration. Donation or loss of whole blood (including clinical trials) within 30 days prior to drug administration (or 56 days for ≥500 mL). Participation in a clinical trial that involved administration of an investigational medicinal product within 30 days prior to drug administration, or recent participation in a clinical investigation that, in the opinion of the Investigator, would jeopardize subject safety or the integrity of the study results. Received any type of live vaccine within 30 days prior to drug administration. Use of medication within 30 days prior to drug administration. On a special diet within 30 days prior to drug administration. Have had a tattoo or body piercing within 30 days prior to drug administration. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The following PK parameters will be estimated for mometasone and azelastine: • Cmax, AUCt, AUCinf, Tmax, Kel, and Thalf
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Blood samples will be taken for mometasone and azelastine PK analysis: Cohort 1: Prior to dosing (0-hour) and at 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 hours post-dose (10 time points) Cohort 2: Prior to dosing (0-hour) and at 0.167, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose (21 time points) |
|
E.5.2 | Secondary end point(s) |
Safety monitoring: • Temperature: daily during confinement • Health monitoring: throughout the study • Vital signs (BP and PR): pre-dose and at 3 and 12 hours post-dose • Adverse events (AEs): monitored throughout the study • Investigator monitoring: prior to drug administration until 4 hours after the last subject is dosed and on-call throughout the study • Cohort 1: a pediatrician will supervise the Parent/Legal Guardian Informed Consent and Adolescent Assent process, monitor Period 1 drug administration at a minimum, and will monitor pediatric AEs onsite or on-call throughout the study • Nasal cavity examination: at screening, each check-in (any time after check-in until prior to dosing), check- out, and at the end of the study |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
During confinement in the clinic and throughout the study. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
comparable pharmacokinetic study (combination versus mono products) |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
Will this trial be conducted at a single site globally?
| Yes |
E.8.4 | Will this trial be conducted at multiple sites globally? | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |